Member Info for Nolupus

Once the science is right , one can invest LT and ignore the UP’s and Downs that traders create .

This can retrace proportionally to the rise but that’s only normal and therefore i personally don’t care ..as I have a LT view of where this is going :-)

But everyone to their own

« You can lead a horse to water, but you can't make him drink »
The same can be said for donkeys and illiterate posters ( will mention no names )

Whilst not always in agreement with posters , we should be able to agree to disagree without the foul language, imo

Was’nt expecting 7p today but am expecting a lot more in 2023

Wait and see but everyone to their own trades and convictions

He is very punctual with his TR-1 , so we should see something in the next 48hrs , imo

The volume is quite impressive so some big buyers around

The SP is just toooooo ridiculous..

Easyp,

Can’t compare the two, imo but Surprise out of the blue with EVG :-)

Must be happy now ..

Let’s see if we get another TR-1

Easyp,

Patience is a virtue ..

Lot’s to look forward to in 2023 .

Some Excellent News !

Well done all

Slightly odd, indeed …

Two sides to every coin , comes to mind but we won’t go there today

Let’s see what next week brings

Do you think that the CNRS who are dual patent owners would be satisfied with a takeover ?

Lot’s of nitty gritty to solve, imo

Todays RNS follows the dilution of IMM’s holdings in Incanthera due to this …

https://uk.advfn.com/stock-market/AQSE/incanthera-INC/share-news/Incanthera-PLC-Issue-of-Equity/89149987

Fast track status is given IF the indication is classed as having an unmet medical need .
Lupus/ SLE is classed in that category so ANY company doing clinical trials in SLE will get fast track status , if they apply for it

Any sane person would know that there are many insane people on this board ( besides myself ) :-)

We all recognize the potential here but it would be great to see more turnover and contracts .

Like Trevor, holding for gold ( whenever )

Notaflipper,

I have read the other board , and I can see what you mean by your last comment .
Many questions remain which we will just have to wait for additional information to be able to make any precise commentary , is all I can say …

Notaflipper,

I wasn’t aware of those discussions

I will pop over there as I have great esteem for SK ..

This is the dosing used in the PK study

´´ Subcutaneous injection of P140 (in both 200 microgram ("mcg") and 800 mcg doses (note: 1mcg = 1 millionth of a gram) showed a clear time and dose-related PK profile which is detectable in the blood of human volunteers and applicable for all potential clinical dosing regimens of P140



· The final group of subjects completed dosing on 30 March 2022. This was a group of subjects that received an intravenous injection of a 800 mcg dose of P140, which showed successful measurement of the absolute bioavailability of the drug (as a control) ‘´

Again the summary from this morning’s update is too succinct to be able to judge properly, imo

´´In summary, the FDA response earlier this month, recommended assessing the potential to use higher dosing in the next clinical program of Lupuzor™ in Lupus, to optimise the clinical benefit to Lupus patients and to maximise efficacy. In addition, the FDA made additional recommendations on clinical measurements, again to support Lupuzor™ through the regulatory process to approval‘´

Those that mean that the FDA recommended using a higher dose than in the last PK study ?

Notaflipper,

What most people don’t take into consideration is that Lupuzor 1 is out the window and Lupuzor2 is better designed and will have a much more robust dossier and therefore a much better chance on eventually gaining approval , imo

The implications are considerable for IMM and therefore, the negotiations/ discussions with Avion will seal the outcomes, imo